Pembrolizumab and nivolumab (targeting PD-1) and ipilimumab (targeting CTLA-4) have been applied in GC treatment with encouraging anti-tumor results (Joshi and Badgwell, 2021). The gene discussed is CTLA4; the disease is gastric cancer.